Relationship between clinical characteristics, RPS6KB1 & p-RPS6KB1 expression and survival time (Univariate analysis).

<p>Relationship between clinical characteristics, RPS6KB1 & p-RPS6KB1 expression and survival time (Univariate analysis).</p

Relationship between RPS6KB1 & p-RPS6KB1 expression and survival time.

<p>Relationship between RPS6KB1 & p-RPS6KB1 expression and survival time.</p

Clinical characteristics and the 5-year overall survival (OS) of NSCLC patients.

<p>Kaplan-Meier survival analyzed the correlation between the clinical characteristics and 5-year OS of NSCLC patients. The figures showed gender, age, tumor histological type, histological differentiation, tumor size, regional lymph node involved, distant metastasis, and clinical stage in order. (<i>Log Rank</i> test).</p

Expression of RPS6KB1 and p-RPS6KB1 in NSCLC and normal lung tissues (IHC staining).

<p>Expression of RPS6KB1 and p-RPS6KB1 in NSCLC and normal lung tissues (IHC staining).</p

Relationship between clinical characteristics and survival time (<i>Log Rank</i>).

<p>Relationship between clinical characteristics and survival time (<i>Log Rank</i>).</p

Expression of RPS6KB1 and p-RPS6KB1 in tumor tissues and the 5-year overall survival (OS) of NSCLC patients.

<p>Kaplan-Meier survival analyzed the correlation between RPS6KB1 expression (A) and p-RPS6KB1 expression (B) and the 5-year OS of NSCLC patients, who were classified as negative expression (Blue) or positive expression (Red). (<i>Log Rank</i> test).</p

Expression of RPS6KB1 and p-RPS6KB1 NSCLC samples and controls.

<p>(A, B) Representative images of negative expression of total RPS6KB1 in normal alveolar tissue and bronchial tissue (× 100). (C, D) Representative images of strong expression of total RPS6KB1 in lung adenocarcinoma and squamous cell carcinoma (× 200). (E, F) Representative images of negative expression of p-RPS6KB1 in normal alveolar tissue and bronchial tissue (× 100). (G, F) Representative images of strong expression of p-RPS6KB1 in lung adenocarcinoma and squamous cell carcinoma (× 200).</p

Protein expression of RPS6KB1, p-RPS6KB1, rpS6 and p-rpS6 after the treatment by various LY2584702 concentrations for 24 h.

<p>Western blot analysis of RPS6KB1, p-RPS6KB1, rpS6 and p-rpS6 in adenocarcinoma cell line A549 and squamous cell carcinoma cell line SK-MES-1 with various LY2584702 concentrations. DMSO without any LY2584702 were expressed as a concentration of 0. β-actin was used as a loading control.</p

elationship between clinical characteristics, RPS6KB1 & p-RPS6KB1 expression and survival time (Multivariate Cox regression model with the Method of Forward <i>LR</i>).

<p>elationship between clinical characteristics, RPS6KB1 & p-RPS6KB1 expression and survival time (Multivariate Cox regression model with the Method of Forward <i>LR</i>).</p

Relationship between clinical characteristics and RPS6KB1 & p-RPS6KB1 expression.

<p>Relationship between clinical characteristics and RPS6KB1 & p-RPS6KB1 expression.</p